Target intelligence / Profile preview

Small intestine absorption (HIA)

Target
HIA
Molecular classification
Other (Biological Process)
01

Overview

Small intestine absorption is the physiological process by which nutrients, electrolytes, water, and xenobiotics (including drugs) are transported from the intestinal lumen across the epithelial lining into the systemic circulation. This process occurs primarily in the duodenum, jejunum, and ileum via mechanisms such as passive diffusion, paracellular transport, and active carrier-mediated transport. Key molecular players in this process include transporters like Solute Carrier (SLC) family members (e.g., SGLT1 for glucose, PepT1 for peptides) and ATP-binding cassette (ABC) efflux pumps like P-glycoprotein. While essential for life and a fundamental pharmacokinetic parameter in drug development (the 'A' in ADME), "Small intestine absorption" is a complex biological pathway rather than a single molecular target. Impairment of this process leads to malabsorption syndromes, while therapeutic modulation often involves targeting specific constituent enzymes or transporters to treat conditions like obesity, diabetes, or hypercholesterolemia.

Other names
Intestinal absorptionGastrointestinal absorptionEnteral absorptionHuman intestinal absorption (HIA)Small bowel absorption
02

Mechanism of action

Modulation of intestinal absorption typically involves the inhibition of specific digestive enzymes (e.g., alpha-glucosidase) or membrane transporters (e.g., NPC1L1) to reduce the uptake of dietary components or the use of pro-absorptive agents to enhance nutrient retention.

03

Biological functions

Nutrient absorptionDrug transportElectrolyte homeostasisWater reabsorptionFirst-pass metabolism
04

Disease associations

Malabsorption syndromeCeliac diseaseCrohn's diseaseShort bowel syndromeInflammatory bowel disease (IBD)ObesityType 2 diabetes
05

Safety considerations

Nutritional deficienciesDrug-drug interactions (DDIs)Gastrointestinal distress (diarrhea, bloating, steatorrhea)Variable drug bioavailabilityElectrolyte imbalance
06

Interacting drugs

Ezetimibe

5 more in the full profile.

07

Biomarkers

D-xylose absorptionPlasma citrulline (enterocyte mass marker)Fecal fat levels7-alpha-hydroxy-4-cholesten-3-one (C4) for bile acid malabsorption

Beyond the preview

Go deeper on Small intestine absorption (HIA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Small intestine absorption (HIA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call